Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Sonographic Thigh Adjustment Ratio and Subcutaneous Fat Thickness as Predictors of Genicular Nerve Block Response in Knee Osteoarthritis (STAR-GNB)

13 de agosto de 2026 actualizado por: Gaziosmanpasa Research and Education Hospital

Sonographic Thigh Adjustment Ratio and Subcutaneous Fat Thickness as Predictors of Genicular Nerve Block Response in Patients With Knee Osteoarthritis Undergoing Genicular Nerve Block: A Prospective Observational Study

Knee osteoarthritis (KOA) is a leading cause of chronic pain and disability. Although genicular nerve block (GNB) is an effective treatment for many patients, treatment response varies considerably. Identifying imaging biomarkers that predict clinical response may improve patient selection and optimize treatment outcomes.

This prospective observational study aims to evaluate whether the Sonographic Thigh Adjustment Ratio (STAR), calculated as anterior quadriceps muscle thickness divided by body mass index (BMI), and subcutaneous fat thickness are associated with pain relief following genicular nerve block in patients with symptomatic knee osteoarthritis. Ultrasound measurements will be obtained before the procedure, and clinical outcomes will be assessed during follow-up. The primary objective is to determine whether sonographic muscle parameters can predict treatment response after GNB.

Descripción general del estudio

Descripción detallada

Knee osteoarthritis is one of the most common musculoskeletal disorders worldwide and is frequently associated with chronic pain, impaired mobility, and reduced quality of life. Genicular nerve block has become an established minimally invasive treatment for patients with persistent pain despite conservative management. However, substantial variability exists in treatment response, highlighting the need for reliable predictors of clinical success.

Recent studies have suggested that ultrasound-derived muscle measurements may provide objective information regarding muscle quality and sarcopenia. The Sonographic Thigh Adjustment Ratio (STAR), defined as anterior quadriceps muscle thickness normalized to body mass index (BMI), has been proposed as an ultrasound-based indicator of muscle mass. Nevertheless, its potential role in predicting the response to interventional pain procedures has not been investigated.

This prospective observational cohort study will enroll patients with symptomatic knee osteoarthritis who undergo ultrasound-guided genicular nerve block as part of routine clinical care. Before the procedure, ultrasound measurements of anterior quadriceps muscle thickness and subcutaneous fat thickness will be obtained. STAR will be calculated by dividing anterior quadriceps muscle thickness by BMI. Clinical outcomes will be assessed using validated pain and functional outcome measures during follow-up.

The primary objective is to evaluate whether STAR predicts treatment response after genicular nerve block. Secondary objectives include investigating the predictive value of quadriceps muscle thickness and subcutaneous fat thickness individually and exploring their relationship with pain reduction and functional improvement.

Tipo de estudio

De observación

Inscripción (Estimado)

30

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

      • Istanbul, Turquía (Türkiye), 34255
        • Reclutamiento
        • University of Health Sciences Gaziosmanpaşa Physical Therapy and Rehabilitation Training and Research Hospital
        • Contacto:
          • Tuğçe Yavuz Mollavelioğlu, Medical Doctor
          • Número de teléfono: +905056751666
          • Correo electrónico: tugceyavuz@hotmail.com.tr
        • Contacto:
        • Investigador principal:
          • Tuğçe Yavuz Mollavelioğlu, Medical Doctor

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Adulto
  • Adulto Mayor

Acepta Voluntarios Saludables

No

Método de muestreo

Muestra no probabilística

Población de estudio

Adults with symptomatic bilateral Kellgren-Lawrence grade 3-4 knee osteoarthritis referred from the Department of Physical Medicine and Rehabilitation to the Pain Medicine Clinic for ultrasound-guided genicular nerve block after failure of conservative treatment. Consecutive eligible patients meeting the inclusion criteria will be enrolled prospectively.

Descripción

Inclusion Criteria:

  • Age ≥45 years.
  • Symptomatic bilateral knee osteoarthritis with Kellgren-Lawrence grade 3 or 4.
  • Visual Analog Scale (VAS) pain score ≥4 at rest or during movement.
  • Scheduled to undergo first ultrasound-guided genicular nerve block.
  • No intra-articular knee injection within the previous 3 months.
  • Considered unsuitable for or awaiting total knee arthroplasty.
  • Ability to provide written informed consent.

Exclusion Criteria:

  • Inflammatory arthritis, rheumatoid arthritis, or crystal arthropathy.
  • Previous knee surgery or knee prosthesis.
  • Active local or systemic infection.
  • Anticoagulant therapy or bleeding disorders.
  • Contraindication to corticosteroids (including uncontrolled diabetes mellitus).
  • Allergy to study medications.
  • Neurological disorders causing neuropathic knee pain.
  • Dementia or inability to complete study assessments.
  • Additional interventional procedures or surgery during follow-up.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

Cohortes e Intervenciones

Grupo / Cohorte
Intervención / Tratamiento
Patients With Knee Osteoarthritis Undergoing Genicular Nerve Block
Adults with symptomatic Kellgren-Lawrence grade 3-4 knee osteoarthritis undergoing ultrasound-guided genicular nerve block as part of routine clinical care. Participants undergo baseline ultrasonographic assessment of quadriceps muscle thickness, subcutaneous fat thickness, and calculation of the Sonographic Thigh Adjustment Ratio (STAR), followed by clinical follow-up at 1 and 3 months.
Ultrasound-guided genicular nerve block was performed as part of routine clinical care in patients with symptomatic knee osteoarthritis. The superomedial, superolateral, and inferomedial genicular nerves were targeted using a standardized ultrasound-guided technique. A standardized injectate consisting of bupivacaine, dexamethasone, and normal saline was administered to each target nerve. The procedure was performed by an experienced pain physician using the same protocol for all participants.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Treatment Response at 1 Month Following Genicular Nerve Block
Periodo de tiempo: 1 month
Treatment response will be defined as a ≥50% reduction in Visual Analog Scale (VAS) pain score from baseline at 1 month after ultrasound-guided genicular nerve block. The predictive value of baseline Sonographic Thigh Adjustment Ratio (STAR) for 1-month treatment response will be evaluated.
1 month

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Responder Pattern After Genicular Nerve Block
Periodo de tiempo: 1 month, and 3 months
Participants will be classified according to pain response pattern after genicular nerve block: non-response, defined as less than 50% reduction in VAS pain score at 1 month; transient response, defined as at least 50% reduction at 1 month but less than 50% reduction at 3 months; and sustained response, defined as at least 50% reduction at both 1 and 3 months. The association between baseline STAR and responder pattern will be evaluated.
1 month, and 3 months
WOMAC Score
Periodo de tiempo: Baseline, 1 month, and 3 months
The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) is a self-administered questionnaire used to evaluate knee and hip osteoarthritis. The global score ranges from 0 to 96, where 0 represents the best possible outcome (no pain or functional limitations) and 96 represents the worst possible outcome (severe pain and maximal functional limitations). Higher scores indicate a worse clinical outcome.
Baseline, 1 month, and 3 months
Five Times Sit-to-Stand Test
Periodo de tiempo: Baseline, 1 month, and 3 months

Change in functional performance assessed using the Five Times Sit-to-Stand (5xSTS) test.

The Five Times Sit-to-Stand (5xSTS) test assesses functional lower extremity strength and transitional movements. The outcome is recorded as the total time (in seconds) required for the participant to complete five consecutive sit-to-stand cycles as quickly as possible from a standard chair. The minimum possible time is 0 seconds, and a maximum cutoff score of 30 seconds is applied for participants who are unable to complete the task. Higher scores (longer times) indicate a worse outcome (poorer functional performance and lower extremity strength).

Baseline, 1 month, and 3 months
Change in Pain Intensity
Periodo de tiempo: Baseline, 1 month, and 3 months

Change in Visual Analog Scale (VAS) pain score from baseline after ultrasound-guided genicular nerve block.

Pain intensity is assessed using the Visual Analog Scale (VAS). The scale consists of a horizontal line where the minimum value is 0 (representing "no pain") and the maximum value is 10 (representing "the worst possible pain"). Participants mark their current pain level on this line. Higher scores indicate a worse outcome (greater pain intensity).

Baseline, 1 month, and 3 months

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

15 de mayo de 2026

Finalización primaria (Estimado)

1 de septiembre de 2026

Finalización del estudio (Estimado)

1 de noviembre de 2026

Fechas de registro del estudio

Enviado por primera vez

14 de julio de 2026

Primero enviado que cumplió con los criterios de control de calidad

14 de julio de 2026

Publicado por primera vez (Actual)

17 de julio de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

17 de agosto de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

13 de agosto de 2026

Última verificación

1 de julio de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

INDECISO

Descripción del plan IPD

The investigators have not yet made a final decision regarding individual participant data (IPD) sharing. Data sharing will be considered after study completion in accordance with institutional policies, ethical requirements, and applicable data protection regulations.

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir